Teneligliptin hydrobromide is a dipeptidyl peptidase-4 (DPP-4) inhibitor, an antidiabetic agent prescribed for the management of type 2 diabetes mellitus by increasing insulin secretion and suppressing… Read more
Teneligliptin hydrobromide is a dipeptidyl peptidase-4 (DPP-4) inhibitor, an antidiabetic agent prescribed for the management of type 2 diabetes mellitus by increasing insulin secretion and suppressing glucagon release. In pharmaceutical analysis, reference standards of teneligliptin hydrobromide and its related compounds—including specific isomers, process-related impurities, metabolites, and stable isotope-labelled compounds—are critical tools for quality control and regulatory compliance. Analytical laboratories utilize these high-quality materials for impurity profiling, method validation, and accurate quantification of the active pharmaceutical ingredient during stability testing and batch release. By providing characterized standards that mimic the profile of potential degradants or synthetic byproducts, these materials ensure the precision of chromatographic and mass spectrometric assays throughout the drug development lifecycle. Maintaining access to such comprehensive analytical standards is essential for verifying the purity, identity, and safety of teneligliptin-based formulations.